Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study

Medical and Pediatric Oncology

Volumn 34, Issue 1, 2000, Pages 10-13

  Fried, Getta ^a,b   Stein, Moshe E ^a   Haim, Nissim ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Cisplatinum; Etoposide; Metastatic breast cancer; Phase II

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANALGESIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; NERVOUS SYSTEM DISEASES; REMISSION INDUCTION; STOMATITIS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 0033979421     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(200001)34:1<10::AID-MPO2>3.0.CO;2-A     Document Type: Article

References (26)

1. Johnson DH, Ruckdeschel JC, Kellen JH, et al. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer 1991; 67:245-249.
2. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990;17(Suppl 2):36-39.
3. Marzla M, Zucchetti M, Colombo N, et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993;4:517-519.
4. Remick SC, McSharry JJ, Wolf BC, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1691-1702.
5. Icli F, Gunel N, Dincol D, et al. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. J Surg Oncol 1992;50:251-253.
6. Cox FB, Burton BC, Olsen GA, et al. Response of refractory breast cancer to a combination of cisplatin and etoposide. Proc Am Soc Clin Oncol 1986;5:64.
7. Krook JE, Loprinzi CL, Schaid DJ, et al. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. Cancer 1990;65:418-421.
8. Cocconi G, Tomato M, DiCostanzo F, et al. Platinum and etoposide in chemotherapy for refractory metastatic breast cancer: a phase II trial of the Italian Oncology Group for Clinical Research. Eur J Cancer 1986;22:761-764.
9. Mabel JA, Little AD: Therapeutic synergism in murine tumors for combination of cisdiammine-dichloroplatinum with VP16-213 or BCNU. Proc AACR-ASCO 1981;22:357.
10. Cocconi G, Bisagni G, Bacchi M, et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991;9:664-669.
11. Giaccone G, Donadio M, Ferrati P, et al. Cisplatin and VP-16 in the treatment of advanced breast carcinoma. Stockholm: ECCO3; 1985. p 170.
12. Athanassiades P, Bacoyiannes H, Kontoyiannes D: Etoposide (VP-16-213) and cis-dichlorodiammine-platinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 1986;5:125-127.
13. Tinsley R, Fuks J, Korean A, et al. Cisplatin and etoposide for advanced breast cancer: a Phase II trial. Proc Annu Soc Clin Oncol 1986;5:74.
14. Miller AR, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
16. Franklin HR, Simonetti GP, Dubbelman AC, et al. Toxicity grading systems: a comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 1994;5:113-117.
17. Durand RF, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987;71:673-679.
18. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral eloposide: a Phase I trial. J Clin Oncol 1989;7:396-401.
19. Palombo H, Estape J, Vinolas N, et al. Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol 1994;33: 527-529.
20. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposde in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-991.
21. Atienza DM, Vogel CL, Trock B, et al. Phase II study of oral VP-16-213 (etoposide) in patients with advanced breast cancer (abstract). Breast Cancer Res Treat 1993;27:146.
22. Bontenbal M, Planting AS, Verweij R, et al. Second-line chemotherapy with long-term low-dose etoposide in patients with advanced breast cancer. Breast Cancer Res Treat 1995;34:135-189.
23. Valero V: Future direction of neoadjuvant therapy for breast cancer. Semin Oncol 1990;25(Suppl 3):36-41.
24. Valero V. Docetaxel as single-agent threapy in metastatic breast cancer: clinical efficacy. Semin Oncol 1997;24(Suppl 13):11-18.
25. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: an overview. Cancer Treat Rev 1996;22:127-142.
26. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a Phase II trial with gemcitabine. J Clin Oncol 1995;3:2731-2736.